FK LABORATORIZ
FK Laboratoriz has developed a drug which is a new structure of a highly specific direct thrombin inhibitor. Its expected pharmacological effects correspond to those stipulated by international standards and enable the product to compete with other medicinal products available at the EEU market. The drug was developed with the use of a combination of computer-based simulation and chemosynthesis, which are modern and recognized methods applied in the pharmaceutical industry.
FK LABORATORIZ
Industry:
Biotechnology Health Care Pharmaceutical
Address:
Moscow, Moscow City, Russian Federation
Country:
Russian Federation
Status:
Active
Total Funding:
174 K USD
Similar Organizations
BionPharma
BionPharma develops and commercializes affordable quality generics and builds strong and effective partnerships.
EpiVax
EpiVax is an immunology company developing comprehensive analytical capabilities in the field of computational immunology.
Laccure AB
Laccure AB has developed a groundbreaking product for easier treatment and prevention of bacterial vaginos (BV).
Investors List
DI Group
DI Group investment in Seed Round - FK Laboratoriz
Primer Capital
Primer Capital investment in Seed Round - FK Laboratoriz